Home › Research › Biomarkers
Multivariate models using NULISAseq and plasma p-tau217 for staging Alzheimer's disease
James D Doecke, Edwin Stage, Christopher Fowler, Vincent Doré, Nils Boehm, Christoph Kleinert, Malleswari Challagundla, Azadeh Feizpour et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-10
Topic: Plasma and spinal-fluid biomarkers
Using a panel of biomarkers was significantly better at predicting disease stage compared with p-tau217 alone; however, the difference was dependent upon p-tau217 assay. Utility of extra BBMs in addition to p-tau217 provides useful information regarding overall disease burden during the separate stages of AD. HIGHLIGHTS: Of the separate assays for p-tau217, the Lumipulse assay demonstrated significantly better performance than the ALZpath assay to separate disease stages. Multivariate blood-based biomarker (BBM) models are significantly better at predicting the presence of A/T from A-T- as compared with any p-tau217 assay. Multivariate BBM models have higher area under the curve values to predict disease stage than Alamar and ALZpath p-tau217, but not Lumipulse p-tau217 during later disease stage comparisons.
Key findings
- Using a panel of biomarkers was significantly better at predicting disease stage compared with p-tau217 alone; however, the difference was dependent upon p-tau217 assay.
- Utility of extra BBMs in addition to p-tau217 provides useful information regarding overall disease burden during the separate stages of AD.
- HIGHLIGHTS: Of the separate assays for p-tau217, the Lumipulse assay demonstrated significantly better performance than the ALZpath assay to separate disease stages.
- Multivariate blood-based biomarker (BBM) models are significantly better at predicting the presence of A/T from A-T- as compared with any p-tau217 assay.
- Multivariate BBM models have higher area under the curve values to predict disease stage than Alamar and ALZpath p-tau217, but not Lumipulse p-tau217 during later disease stage comparisons.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants387
- Evidence strengthLow
How this study scored 55/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 31 of the 56 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 387 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41133401) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 31 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 31 of the 56 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Doecke, J. D., Stage, E., Fowler, C., Doré, V., Boehm, N., Kleinert, C., et al. (2025). Multivariate models using NULISAseq and plasma p-tau217 for staging Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70793
Vancouver
Doecke JD, Stage E, Fowler C, Doré V, Boehm N, Kleinert C, et al. Multivariate models using NULISAseq and plasma p-tau217 for staging Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.70793. PMID: 41133401.
BibTeX
@article{doecke2025-41133401,
author = {Doecke, James D and Stage, Edwin and Fowler, Christopher and Doré, Vincent and Boehm, Nils and Kleinert, Christoph and Challagundla, Malleswari and Feizpour, Azadeh and others},
title = {{Multivariate models using NULISAseq and plasma p-tau217 for staging Alzheimer's disease}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.70793},
pmid = {41133401},
url = {https://doi.org/10.1002/alz.70793}
}
Related studies in Biomarkers
Also tagged “blood-based”
698 studies in the library carry the topic tag “blood-based”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 698 tagged studies.